+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Single center experience with percutaneous endovascular repair of superior vena cava syndrome

Single center experience with percutaneous endovascular repair of superior vena cava syndrome

Catheterization and Cardiovascular Interventions 77(5): 733-739

To demonstrate short-term effectiveness and long-term efficacy of percutaneous transluminal angioplasty (PTA) with or without adjunctive therapy in treatment of superior vena cava syndrome (SVCS). Recently, PTA with or without adjunctive therapy has evolved as first-line therapy for SVCS. Despite growing evidence for PTA with or without adjunctive therapy, there are little data reflecting its short- and long-term outcomes. We retrospectively reviewed 14 consecutive patients undergoing PTA with or without adjunctive therapy for SVCS, between July 2001 and September 2009. A total of 14 patients (nine women; mean age, 49 ± 15 years) with SVCS underwent attempted PTA with or without adjunctive therapy. Causes of SVCS were indwelling catheters or pacemaker wires (n = 5), idiopathic (n = 5), thoracic outlet syndrome (n = 2), and cancer-related thrombosis (n = 2). Obstruction of the SVC involved inflow branches in 86% of patients (n = 12). PTA with or without adjunctive therapy was attempted in all 14 patients and was angiographically successful in 93% (n = 13). PTA and stenting was performed in eight (57%) patients; three (21%) patients had PTA with thrombectomy/thrombolysis; one (7%) patient had PTA alone; and one (7%) patient had thrombectomy/thrombolysis alone. Symptom relief was seen in 86% (n = 12), and initial patency was 90%. There were no procedural complications. Mean follow-up was 12 months, and no deaths were reported. In the 11 (79%) patients with follow-up imaging, nine (82%) patients showed patency and two (18%) had residual symptoms, with one patient undergoing surgery. PTA with adjunctive endovascular stent therapy for SVCS is safe and effective at giving both rapid and sustained symptom relief.

(PDF same-day service: $19.90)

Accession: 055793434

Download citation: RISBibTeXText

PMID: 21061246

DOI: 10.1002/ccd.22871

Related references

Superior Vena Cava Rupture and Cardiac Tamponade Complicating the Endovascular Treatment of Malignant Superior Vena Cava Syndrome: A Case Report and Literature Review. Seminars in Interventional Radiology 32(4): 439-444, 2015

Endovascular treatment of superior vena cava syndrome by percutaneous venoplasty. Heart, Lung & Circulation 19(11): 681-683, 2011

Migration of an endovascular stent from superior vena cava to the right ventricular outflow tract in a patient with superior vena cava syndrome. Angiology 59(1): 114-116, 2008

Percutaneous endovascular catheter aspiration thrombectomy of severe superior vena cava syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition 87(1): F64-F66, 2002

Tours experience of endovascular treatment in superior vena cava syndrome. Journal des Maladies Vasculaires 37(3): 118-123, 2012

Open surgery repair for superior vena cava syndrome after failed endovascular stenting. Annals of Thoracic Surgery 97(4): 1445-1447, 2014

Superior vena cava syndrome. Experience with endovascular stents and surgical therapy. Surgical Clinics of North America 79(3): 683-94, Xi, 1999

Percutaneous endovascular management of chronic superior vena cava syndrome of benign causes : long-term follow-up. European Radiology 27(1): 97-104, 2016

Superior vena cava syndrome: Experience at the Hacettepe Medical Center. Annals of Saudi Medicine 12(6): 587-589, 1992

Bridging stent placement through the superior vena cava to the inferior vena cava in a patient with malignant superior vena cava syndrome and an iodinated contrast material allergy. Japanese Journal of Radiology 32(8): 496-499, 2015

Superior vena cava resection for lung and mediastinal malignancies: a single-center experience with 70 cases. Annals of Thoracic Surgery 83(1): 223-9; Discussion 229-30, 2006

Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer. Lung Cancer 43(2): 209-214, 2004

15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer. Lung Cancer 45(3): 357-363, 2004

Severe superior vena caval syndrome after the Mustard repair in a patient with persistent left superior vena cava. European Journal of Cardio-Thoracic Surgery 8(1): 48-50, 1994